Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD5 | P21918 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19557301 | 0.88 | LTA4H (0.75) | LTA4HSIGMAR1ALDH1A1KMT2AHTT | |
| SCHEMBL26981197 | 0.88 | LTA4H (0.75) | LTA4HSIGMAR1ALDH1A1KMT2AHTT | |
| SCHEMBL5321100 | 0.85 | ATM (0.58) | LTA4HPOLBSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL29447351 | 0.84 | LTA4H (0.87) | LTA4HSIGMAR1ALDH1A1KMT2ADRD1 | |
| SCHEMBL31305362 | 0.84 | LTA4H (0.71) | LTA4HSIGMAR1ALDH1A1KMT2ARAB9A | |
| SCHEMBL13783262 | 0.84 | POLB (0.54) | LTA4HPOLBSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL21887008 | 0.84 | LTA4H (0.50) | LTA4HPOLBSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL3118449 | 0.84 | TSHR (0.48) | LTA4HPOLBSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL5326365 | 0.83 | ALDH1A1 (0.48) | LTA4HPOLBSIGMAR1ALDH1A1DRD1 | |
| SCHEMBL6393260 | 0.83 | LTA4H (0.84) | LTA4HSIGMAR1ALDH1A1DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-112707907-B | Purine derivative and intermediate thereof, and application of purine derivative and intermediate thereof in preparation of anti-cancer drugs | 张飞 | 2023-05-23 | — | — | CN | disclosed |
| US-20220389017-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2021078141-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | 苏州锐明新药研发有限公司 | 2021-04-29 | — | — | WO | disclosed |
| WO-2020063636-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | 苏州锐明新药研发有限公司 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389017-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | PNP, ENTPD5, NTPCR | LTA4H 3132/4885POLB 471/4885SIGMAR1 2822/4885 |
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | PIK3CA, PIK3CD, PIK3R5 | LTA4H 2624/4885POLB 2123/4885SIGMAR1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.